Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, Administered in Combination With ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
Brief Summary: This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a cisplatin-based highly emetogenic chemotherapy.


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone, Drug: palonosetron hydrochloride, Drug: prochlorperazine, Drug: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: granisetron hydrochloride, Drug: prochlorperazine, Drug: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: aprepitant, Drug: dexamethasone, Drug: palonosetron hydrochloride, Drug: placebo | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: palonosetron hydrochloride, Drug: prochlorperazine, Drug: placebo | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV | Intervention Type: DRUG; Name: granisetron hydrochloride; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: palonosetron hydrochloride; Assigned to Arm(s): Arm I, Arm III, Arm IV | Intervention Type: DRUG; Name: prochlorperazine; Assigned to Arm(s): Arm I, Arm II, Arm IV | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV
B: Intervention Type: DRUG; Name: Oral Casopitant (GW679769); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: IV Casopitant (GW679769); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: IV ondansetron hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral dexamethasone; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: fosaprepitant dimeglumine, Drug: Dexamethasone, Drug: Ondansetron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Aprepitant, Drug: Dexamethasone, Drug: Ondansetron | Intervention Type: DRUG; Name: Comparator: fosaprepitant dimeglumine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Aprepitant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): 1, 2
D: Arm Label: Arm A: Aprepitant, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant, Drug: Placebo | Arm Label: Arm B: Placebo, Then Aprepitant; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant, Drug: Placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Arm A: Aprepitant, Then Placebo, Arm B: Placebo, Then Aprepitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A: Aprepitant, Then Placebo, Arm B: Placebo, Then Aprepitant

Answer: B